ClinicalTrials.gg
RecruitingNCT07846033Updated Sep 29, 2026

A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities

A Phase 1 interventional study of SC VK3019 and Matching placebo in Obese Adults, sponsored by Viking Therapeutics, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Viking Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 999 studies in Weight Loss with a site in United States — 118 open to participants now, 173 under way, 8 of them phase 3. Weight Loss · United States.

Planned enrollment
538th of 916
56 · median 72
Started
2026
with 48 others
Phase 1
35 of 999
4 open now
Primary completion
2026-10
later than 40 of 172 live
Registered
987th of 999
by date

Among the 999 studies in Weight Loss with a site in United States, this one is the 538th largest by planned enrollment of the 916 interventional ones that give a count, is one of 49 that started in 2026, is one of 35 in phase 1, reaches primary completion later than 40 of the 172 other live ones, and was the 987th registered.

Weight Loss

1,820 studies on the registry are indexed under Weight Loss; 298 are open to participants now.

Browse Weight Loss studies →

Open to participants now

118 of the 999 studies in Weight Loss with a site in United States are open now. Recruiting first, the newest first:

112 more — sign in →

All 118 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 199 Weight Loss studies recruiting now, 73 (37%) set no upper age limit and 109 (55%) stop at 75 or younger; 21 take children under 18; 57 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 999 studies in Weight Loss with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, randomized, double-blind, placebo-controlled single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of VK3019 in overweight and obese adults without comorbidities.

Read the detailed description

Approximately 56 participants will enroll into one of 7 cohorts (Cohort 1 through Cohort 7 N=8 per cohort) and will receive either VK3019 or VK3019 matching placebo (for a total of 6 VK3019 and 2 placebo per cohort).

All dose cohorts will first dose 2 sentinels (1 active and 1 placebo) to be followed by the rest of the cohort (ROC) no sooner than 48 hours following sentinel dosing. In all cohorts, the first 2 enrolled participants (sentinel pair) will be randomized in a 1:1 ratio and in a double-blind fashion, to receive either VK3019 or matching VK3019 placebo. The 2 sentinel participants will be dosed on the same day (Day 1). If deemed safe by the Investigator, a minimum 2 days after sentinel pair dosing, the same dose will be administered to the ROC participants. The rest of the participants within cohort will be randomized 5:1 where 1 is the remaining placebo.

Safety Review Committee (SRC) meetings will be held prior to dose escalation during the study in a blinded fashion. The decisions on dose escalation will be based on safety and laboratory data from each cohort.

03

Conditions studied

  • Obese Adults

Browse trials for

Keywords

  • Weight loss
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).
  • Participants must be medically healthy, with no significant medical history, have no abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of the Investigator.
  • ≥ 27 kg/m2 and \< 40 kg/m2.
  • Willing to comply with requirements.

Exclusion criteria

Exclusion Criteria:

  • Participants with any level of disease or organ system dysfunction as identified during physical examination, medical history or laboratory testing, as assessed by the Investigator.
  • Any surgical or medical condition (active or chronic) that may interfere with IP distribution, metabolism, excretion, or drug absorption.
  • History or presence of acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, diabetes, hematological, oncological, or central nervous disorder that in the opinion of the Investigator would pose a significant risk for the participant.
  • Current or prior diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes).
  • History of, or current, clinically significant liver disease, gallbladder disease (with the exception of Gilbert's Syndrome), as assessed by the Investigator.
  • History of drug or alcohol abuse (ie, >14 drinks/week for women or 21 drinks/week for men [1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard liquor]) within 12 months of Screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    VK3019 Dose Level 1

    Single-dose VK3019 or placebo administered subcutaneously

    Drug: SC VK3019 · Drug: Matching placebo

  • Experimental
    VK3019 Dose Level 2

    Single-dose VK3019 or placebo administered subcutaneously

    Drug: SC VK3019 · Drug: Matching placebo

  • Experimental
    VK3019 Dose Level 3

    Single-dose VK3019 or placebo administered subcutaneously

    Drug: SC VK3019 · Drug: Matching placebo

  • Experimental
    VK3019 Dose Level 4

    Single-dose VK3019 or placebo administered subcutaneously

    Drug: SC VK3019 · Drug: Matching placebo

  • Experimental
    VK3019 Dose Level 5

    Single-dose VK3019 or placebo administered subcutaneously

    Drug: SC VK3019 · Drug: Matching placebo

  • Experimental
    VK 3019 Dose Level 6

    Single-dose VK3019 or placebo administered subcutaneously

    Drug: SC VK3019 · Drug: Matching placebo

  • Experimental
    VK3019 Dose Level 7

    Single-dose VK3019 or placebo administered subcutaneously

    Drug: SC VK3019 · Drug: Matching placebo

Interventions

  • DrugSC VK3019

    Single dose VK3019

  • DrugMatching placebo

    Single dose matching placebo

06

What researchers measure

Primary outcomes

  1. Evaluate the safety of single doses of subcutaneous administration of VK3019

    -Incidence of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)

    Time frame: 36 days

Secondary outcomes

  1. Evaluate the Pharmacokinetic profile of single doses of subcutaneous administration of VK3019

    Pharmacokinetic profile of subcutaneous VK3019 by measuring peak plasma concentration (Cmax)

    Time frame: 36 days

07

Study locations

1 of 1 sites recruiting
  • Viking Clinical Site #001
    Lake Forest, California 92630, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Oct 2026, 2 months after the start.

Of 24 phase 1 interventional studies under Weight Loss, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's planned 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2026
First posted
Sep 29, 2026
StartActual
Jul 6, 2026
Primary completionEst.
Oct 2, 2026
CompletionEst.
Nov 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07846033
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Jul 6, 2026
Primary completion
Oct 2, 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Sep 29, 2026

Study contacts

Hubert C Chen, MD
Contact
clinicaltrials@vikingtherapeutics.com
8587044660

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion